



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## SB-332235

Cat. No.:	HY-16981
CAS No.:	276702-15-9
Molecular Formula:	C <sub>13</sub> H <sub>10</sub> Cl <sub>3</sub> N <sub>3</sub> O <sub>4</sub> S
Molecular Weight:	410.66
Target:	CXCR
Pathway:	GPCR/G Protein; Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	SB-332235 is a potent, orally active nonpeptide CXCR2 antagonist, with an IC <sub>50</sub> of 7.7 nM. SB-332235 displays 285-fold selectivity for CXCR2 over CXCR1. SB-332235 inhibits acute and chronic models of arthritis in the rabbit. SB-332235 inhibits viability of AML cells <sup>[1][2]</sup> .								
<b>In Vitro</b>	<p>SB-332235 (1-100 μM; 48 hours) inhibits viability of AML cell lines<sup>[2]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay<sup>[2]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>AML cell</td> </tr> <tr> <td>Concentration:</td> <td>1, 10, 100 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 hours</td> </tr> <tr> <td>Result:</td> <td>Led to a dose-dependent decrease in proliferation in all cell lines.</td> </tr> </table>	Cell Line:	AML cell	Concentration:	1, 10, 100 μM	Incubation Time:	48 hours	Result:	Led to a dose-dependent decrease in proliferation in all cell lines.
Cell Line:	AML cell								
Concentration:	1, 10, 100 μM								
Incubation Time:	48 hours								
Result:	Led to a dose-dependent decrease in proliferation in all cell lines.								
<b>In Vivo</b>	<p>SB-332235 (25 mg/kg, p.o., b.i.d.) exhibits significantly reduced numbers of total leukocytes in synovial fluids from IL-8-injected knees<sup>[1]</sup>. SB-332235 (10-25 mg/kg; p.o.; twice a day for 14 days) inhibits chronic Ag-induced arthritis<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Adult female New Zealand White rabbits (chronic OVA-induced model of arthritis)<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>10, 25 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>P.o.; twice a day for 14 days</td> </tr> <tr> <td>Result:</td> <td>Day-15 synovial fluid leukocyte numbers in OVA-injected knees were significantly reduced in rabbits. The decrease in neutrophils, monocytes, and lymphocytes resulting from treatment with 25 mg/kg of the antagonist was accompanied by a significant reduction in synovial fluid PGE<sub>2</sub>, LTB<sub>4</sub>, LTC<sub>4</sub>, and IL-8 levels.</td> </tr> </table>	Animal Model:	Adult female New Zealand White rabbits (chronic OVA-induced model of arthritis) <sup>[1]</sup>	Dosage:	10, 25 mg/kg	Administration:	P.o.; twice a day for 14 days	Result:	Day-15 synovial fluid leukocyte numbers in OVA-injected knees were significantly reduced in rabbits. The decrease in neutrophils, monocytes, and lymphocytes resulting from treatment with 25 mg/kg of the antagonist was accompanied by a significant reduction in synovial fluid PGE <sub>2</sub> , LTB <sub>4</sub> , LTC <sub>4</sub> , and IL-8 levels.
Animal Model:	Adult female New Zealand White rabbits (chronic OVA-induced model of arthritis) <sup>[1]</sup>								
Dosage:	10, 25 mg/kg								
Administration:	P.o.; twice a day for 14 days								
Result:	Day-15 synovial fluid leukocyte numbers in OVA-injected knees were significantly reduced in rabbits. The decrease in neutrophils, monocytes, and lymphocytes resulting from treatment with 25 mg/kg of the antagonist was accompanied by a significant reduction in synovial fluid PGE <sub>2</sub> , LTB <sub>4</sub> , LTC <sub>4</sub> , and IL-8 levels.								

---

## REFERENCES

---

- [1]. Podolin PL, et al. A potent and selective nonpeptide antagonist of CXCR2 inhibits acute and chronic models of arthritis in the rabbit. *J Immunol.* 2002;169(11):6435-6444.
- [2]. Schinke C, et al. IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells [published correction appears in *Blood.* 2015 Jul 16;126(3):425. Barreyro, Laura [corrected to Barreyro, Laura]]. *Blood.* 2015;125(20):3144-3152.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA